Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | MPO | P05164 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | APAF1 | O14727 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 3/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.68 |
| ▸ | HTR7 | P34969 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Tryptophan SCHEMBL289042 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL475349 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL289043 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL7327 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL475350 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL4732053 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL23141133 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL1120026 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL4732052 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL30343446 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102183-A1 | EFFECTOR CELLS HAVING ENHANCED TARGET CELL RECOGNITION | FATE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20250388646-A1 | ENHANCING EFFECTOR CELL DURABILITY AND EFFICACY IN ADOPTIVE CELL THERAPIES | FATE THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | claimed |
| US-20250360210-A1 | IMMUNOEFFECTOR CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS GENETICALLY ENGINEERED WITH MEMBRANE BOUND IL12 AND USES THEREOF | CENTURY THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | claimed |
| US-20250320521-A1 | ERYTHROPARVOVIRUS COMPOSITIONS AND METHODS FOR GENE THERAPY | SYNTENY THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | claimed |
| US-12435123-B2 | Immunotherapies using enhanced iPSC derived effector cells | FATE THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | claimed |
| US-20250302994-A1 | ERYTHROPARVOVIRUS WITH A MODIFIED GENOME FOR GENE THERAPY | SYNTENY THERAPEUTICS, INC. | 2025-10-02 | — | — | US | claimed |
| US-20250295810-A1 | ERYTHROPARVOVIRUS WITH A MODIFIED CAPSID FOR GENE THERAPY | SYNTENY THERAPEUTICS, INC. | 2025-09-25 | — | — | US | claimed |
| EP-4615876-A2 | GENETICALLY ENGINEERED CELLS HAVING ANTI-NECTIN4 CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOF | Century Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-12398373-B2 | Enhanced immune effector cells and use thereof | FATE THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| EP-3728563-B1 | ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF | FATE THERAPEUTICS INC (US) | 2025-06-18 | — | — | EP | claimed |
| WO-2019178141-A1 | ORGANIC METABOLITE COMPOSITIONS AND METHODS OF USE AS MITICIDES FOR HONEY BEES | NIEMCZURA PAUL (US) | 2019-09-19 | — | — | WO | claimed |
| CN-109892489-A | A kind of resisting stress sow premixed feed and the mixed feed containing it | 河南普爱饲料股份有限公司 | 2019-06-18 | — | — | CN | claimed |
| CN-108651743-A | A kind of disease-resistant fattening feed of rabbit | 道真自治县云庄农牧业发展有限公司 | 2018-10-16 | — | — | CN | claimed |
| CN-108185168-A | A kind of hardening agent of calf milk powder or fresh milk | 北京精准动物营养研究中心 | 2018-06-22 | — | — | CN | claimed |
| US-20170360730-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | claimed |
| CN-107442170-A | A kind of chiral MOF composite catalysts and its preparation method and application | 济南大学 | 2017-12-08 | — | — | CN | claimed |
| CN-106432117-A | Preparation method and application of functional nano-cerium complex | 济南大学 | 2017-02-22 | — | — | CN | claimed |
| CN-103622003-A | Conditioning catering or meal replacement for calmness and peaceful sleep | ZHEJIANG JINSHANMEI BIOTECHNOLOGY CO LTD | 2014-03-12 | — | — | CN | claimed |
| CN-103404845-A | Special diet for insomnia patients | HU ANRAN | 2013-11-27 | — | — | CN | claimed |
| CN-101475565-A | Anti-hypertension compound, and preparation, pharmaceutical composition and use thereof | JIANMIN WANG (CN) | 2009-07-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388646-A1 | ENHANCING EFFECTOR CELL DURABILITY AND EFFICACY IN ADOPTIVE CELL THERAPIES | CD40, TNFRSF9, CD40LG | KMT2A 3076/4885KDM4E 2598/4885MAPT 3428/4885 |
| US-20170360730-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | KMT2A 4432/4885KDM4E 4698/4885MAPT 3603/4885 |
| US-20250302994-A1 | ERYTHROPARVOVIRUS WITH A MODIFIED GENOME FOR GENE THERAPY | ETV1, RNGTT, EIF2AK2 | KMT2A 1644/4885KDM4E 3832/4885MAPT 3696/4885 |
| US-20250320521-A1 | ERYTHROPARVOVIRUS COMPOSITIONS AND METHODS FOR GENE THERAPY | RNGTT, TTPA, ETV1 | KMT2A 2881/4885KDM4E 4360/4885MAPT 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.